A Phase 2a Study Examining the Safety and Efficacy of BOL-DP-o-04 Sublingual Drops for Treating Diabetic Neuropathy
Latest Information Update: 25 Mar 2021
At a glance
- Drugs BOL DP o 04 (Primary)
- Indications Diabetic neuropathies
- Focus Adverse reactions; Therapeutic Use
- Sponsors BOL Pharma
Most Recent Events
- 22 Mar 2021 Status changed from recruiting to discontinued due to company strategic prioritization.
- 19 Sep 2019 Planned End Date changed from 20 Jan 2020 to 20 Dec 2020.
- 19 Sep 2019 Planned primary completion date changed from 20 Jan 2020 to 20 Dec 2020.